Skip to main content

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadeq

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme LLC.

Start Date

May 24, 2024

End Date

May 31, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme LLC.

Start Date

May 24, 2024

End Date

May 31, 2029